Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 344

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 344
---
 Trust Account of $15,127,621.

#### Cash Flows from Financing Activities
For the nine months ended September 30, 2024, net cash provided by financing activities was $497,131, which was a result of the proceeds from the Liminatus promissory note of $2,300,000, offset by the redemption of Iris Class A Common Stock of $1,802,869.

<div align='center'>181</div>

TABLE OF CONTENTS

For the nine months ended September 30, 2023, net cash used in financing activities was $9,913,465, which was a result of Iris Class A Common Stock that was redeemed in December 2022 and September 2023 for $10,657,185, which was offset by proceeds from the promissory note from a related party for $393,720 and the proceeds from the promissory note from Liminatus for $350,000.

For the year ended December 31, 2023, net cash used in financing activities was $9,424,965 which was a result of Iris Class A Common Stock that was redeemed in September 2023 in the amount of $10,358,754, the 2023 adjustment to share price for shares redeemed in December 2022 in the amount of $298,431, which was offset by net proceeds from the promissory note from a related party of $413,720 and proceeds from a promissory note from Liminatus of $818,500.

For the year ended December 31, 2022, net cash used in financing activities was $262,923,913, which was a result of the Iris Class A Common Stock that was redeemed in December 2023 in the amount of $263,963,913, partially offset by proceeds from the promissory note from a related party for $1,040,000.

In connection with Iris’s assessment of going concern considerations in accordance with FASB Accounting Standards Update (“ASU”) 2014-15, Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern, management has determined that Iris has and will continue to incur significant costs in pursuit of its acquisition plans, which raises substantial doubt about Iris’s ability to continue as a going concern. Moreover, Iris may need to obtain additional financing either to complete its initial business combination or because it becomes obligated to redeem a significant number of its public shares upon consummation of its initial business